Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

19 evidence topics · 24 sources

Summary
  • Guideline positioning of targeted biologics: Guidance states that clinicians should seek to initiate available targeted therapies in patients with gMG who have active symptoms and for whom conventional therapy does not achieve symptom control within 6 to 12 months or results in excessive treatment-related burden, with use as initial treatment driven by clinician judgment. Complement and FcRn inhibitors are recommended as second- or third-line treatment in severe MG exacerbations and crisis, and their roles are being established especially in patients unresponsive to conventional therapy. Expert recommendations state that an interclass switch should be considered for inefficacy, intolerable side effects, or patient preferences regarding type and frequency of administration, and that a switch to IVIg interval therapy should be considered when targeted immunotherapies fail.
  • Intended population and setting for Descartes-08: The phase 3 AURORA trial enrolls adults with acetylcholine receptor autoantibody-positive generalized MG and administers six once-weekly outpatient infusions without preconditioning chemotherapy. The company states that the current standard of care consists of chronic steroids and other immunosuppressants and that complement and FcRn inhibitors are typically administered continually, estimates that MG affects over 106,000 patients in the U.S., and describes Descartes-08 as the only CAR-T in autoimmune disease it is aware of that is designed for outpatient administration without preconditioning chemotherapy. The company states that conventional DNA cell therapies are administered under close monitoring in an inpatient setting. Investigators of an earlier Descartes-08 study reported the feasibility of preparing the cells for patients on immunosuppressive therapy, using them without lymphodepletion chemotherapy, and administering them in the outpatient setting with minimal post-infusion monitoring, and a later publication describes a “biologic-like approach that involves an initial leukapheresis”. An investigator quoted by the company described outpatient retreatment without lymphodepleting chemotherapy as a potential option for patients who have cycled through multiple therapies.
  • Recommendations on cellular therapy: EBMT recommendations state that cellular therapy in autoimmune diseases should be performed within a clinical trial whenever possible, at expert centres with JACIE accreditation for immune effector cell administration, that the need for and dose of lymphodepletion are not established, and that repeated dosing of BCMA CAR-T has been efficacious in MG without lymphodepletion. A 2026 article on CAR-T therapy in autoimmune disease states that current neurological evidence is limited to small early-phase studies and case reports, with one placebo-controlled trial (generalised MG), and that CAR-T therapy should be considered experimental and delivered in specialised centres.
  • Other CAR-T approaches in MG: In a study of anti-BCMA/CD19 bispecific CAR-T cells given as a single infusion after fludarabine and cyclophosphamide lymphodepletion, 18 participants were enrolled; grade 1 cytokine release syndrome occurred in 39%, and among 17 who completed follow-up, MG-ADL improved by −8.6 (95% CI −10.2 to −7.0) and QMG by −15.4 (−17.6 to −13.2) by day 180, and 14 (82%) achieved minimal manifestations. Three patients with treatment-resistant MG treated with anti-CD19 CAR-T cells (KYV-101) after cyclophosphamide and fludarabine lymphodepletion achieved sustained remission for at least 19 months, and BCMA-directed CAR-T cells in two patients (one AChR-IgG, one MuSK-IgG) produced clinical improvement over 18 months. KYV-101 is being compared with standard-of-care immunosuppressive therapy in the phase 2/3 KYSA-6 study, and CABA-201 is being evaluated with cyclophosphamide and fludarabine and, at escalating doses, without that preconditioning.
  • REMS change for approved CAR-T therapies: The FDA eliminated the REMS for currently approved BCMA- and CD19-directed autologous CAR T cell immunotherapies, removing the requirements for specially certified dispensing sites with on-site, immediate access to tocilizumab. Labeling now calls for monitoring for at least two weeks, including daily monitoring for at least one week, remaining near a healthcare facility for at least two weeks, and avoiding driving for two weeks. In 58 patients with myeloma, lymphoma, or acute lymphoblastic leukemia who received CAR T-cell infusion as outpatients and were seen daily for the first 7 to 10 days, 17 (41%), 16 (38%), and 9 (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30.
Care setting compared with conventional DNA-based CAR-T cell therapy
BCMA/CD19 bispecific CAR T-cell therapy after fludarabine and cyclophosphamide lymphodepletion: single-arm phase 1 trial, 18 participants with refractory gMG

“Participants received lymphodepleting chemotherapy with fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day) for three consecutive days (days −5 to −3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Between May 3, 2023, and June 19, 2024, 18 patients were enrolled and received apheresis and a single CAR T cell infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The anti-BCMA/CD19 bispecific CAR T cells were generally safe, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome, and only grade 1 cytokine release syndrome (39% of patients). The most common grade 3 or worse adverse events within 28 days were hematological toxicities, including three leukopenia, three neutropenia, one anaemia, and one thrombocytopenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“17 participants completed follow-up. Clinical improvements by day 180 were −8.6 (95% CI −10.2 to −7.0) for MG-ADL score and −15.4 (−17.6 to −13.2) for QMG score. 14 participants (82%) achieved minimal manifestations, 15 (88%) stopped glucocorticoids, all stopped non-steroidal immunosuppressants, and eight (47%) had anti-acetylcholine receptor antibody negative seroconversion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

FDA elimination of REMS for approved autologous CAR T-cell therapies, June 2025